Blend of tetraselmis suecica extract and laminaria saccharina ferment for the reduction of sebum production

Abstract

The present invention relates to a blend Tetraselmis suecica extract and Laminaria saccharina ferment. Further, the present invention relates to a cosmetic or pharmaceutical composition related to a blend Tetraselmis suecica extract and Laminaria saccharina ferment for topical application. Further, the present invention relates to a use of a cosmetic or pharmaceutical composition for sebum and / or pore size reduction of the human or animal skin.

Description

[0001] Blend of Tetraselmis suecica extract and Laminaria saccharina ferment for the reduction of sebum production

[0002] The present invention relates to a blend Tetraselmis suecica extract and Laminaria Saccharina ferment. Further, the present invention relates to a cosmetic or pharmaceutical composition related to a blend Tetraselmis suecica extract and Laminaria Saccharina ferment for topical application. Further, the present invention relates to a use of a cosmetic or pharmaceutical composition for sebum and / or pore size reduction of the human or animal skin.

[0003] Further aspects of the present invention will arise from the description below, in particular from the examples, as well as from the attached patent claims.

[0004] Sebaceous glands (SGs) are specialized skin structures located across the body, except on the palms, soles, and dorsum of the feet. These glands can exist as single or multiple lobules within a gland. SGs produce sebum, a natural oil that contributes to the hydrolipidic film on the skin. Human sebum is a complex mix, comprising about 40-60% triglycerides, diglycerides, and free fatty acids, 25-30% wax esters, 12-15% squalene, 3-6% cholesterol esters, and 1 .5-2.5% cholesterol. Sebum plays a crucial role in skin health and appearance, offering barrier protection, regulating water loss through the skin, reducing friction for skin and hair, maintaining skin biofilm, and delivering antioxidants like squalene, coenzyme Q10, and vitamin E to the skin surface. It also contributes to epidermal development, body odor, pheromone production, hormonal signalling, epidermal differentiation, and protection from UV radiation, and influences the skin's natural micro-flora. SGs come in two types: those linked to hair follicles in pilosebaceous units, and independent ones, which are not linked to hair follicles. The former may surround each hair follicle, with arrector pili muscles around the glands being attached to the hair follicles. SGs are abundant on the face, scalp, and back's midline, reaching 400-900 glands / cm2on the face. They also exist in hairless areas like, nose, penis, labia minora, nipples, and as specialized forms, adapted to their specific locations and functions. This is the case for the eyelids (meibomian glands), ears (ceruminous glands) and inner oral cheek mucosa (Fordyce's spots).

[0005] Sebocytes are the principal cells in sebaceous glands (SGs), primarily responsible for producing and secreting sebum through a distinctive process known as holocrine secretion. This involves the differentiation and disintegration of fully mature sebocytes. Sebocytes can be categorized into undifferentiated cells that form a single layer adjacent to the basal lamina. These cells exhibit stem cell-like properties, generating a continuous flow of proliferating and differentiating cells. As these basal cells move towards the center of the gland lobules, they progressively differentiate into early, advanced, fully differentiated, and eventually mature sebocyte stages. A notable characteristic of this process is the increasing accumulation of lipids in the sebocytes' cytoplasm as they mature. In the final stages of differentiation, the sebocytes' nuclei distort and disintegrate, leading to cell rupture. The sebum then moves into the sebaceous duct, eventually being released around the hair shaft within the hair follicle. Post-secretion, the sebum is colonized by various microorganisms, whose growth is regulated by several defense mechanisms and exposure to ambient oxygen. The interaction with oxygen and microbes alters the sebum's composition, with the breakdown of triglycerides into fatty acids being a significant change.

[0006] Sebocytes have the enzymatic capability to synthesize all lipid classes found in sebum, featuring a diverse range of fatty acids including various chain lengths, unsaturation levels, and both linear and branched types. These fatty acids are produced using substrates like acetate and propionate, extended by two-carbon units from malonyl-CoA, and desaturated by specific enzymes. Linoleic acid plays a crucial role in sebaceous lipid synthesis, converting into two-carbon precursors for acetyl-CoA, leading to squalene and wax ester formation. The concentration of linoleic acid in sebocytes is likely regulated by its plasma levels. Sebocytes also synthesize triglycerides, cholesterol, and wax esters. Triglycerides are formed from fatty acids and glycerol, involving enzymes like MGAT and DGAT. Wax esters are produced through a two-step process involving fatty-acyl-CoA reductase and wax synthase, with a preference for saturated fatty acids. ACAT 1 enzyme facilitates the incorporation of cholesteryl esters into cytoplasmic lipid droplets in sebaceous glands. Both cholesterol and squalene share initial biosynthesis steps, with squalene being a key intermediate in cholesterol synthesis.

[0007] Liver-X receptors (LXRs) and peroxisome proliferator-activated receptors (PPARs), both part of the nuclear hormone receptor (NHR) family, are crucial in regulating cholesterol homeostasis, lipid metabolism, and sebocyte function. LXRs, when activated in SZ95 sebocytes, increase lipid droplet accumulation, likely due to upregulation of LXRa receptor and targets like FASN and SREBP-1 . PPARs, activated by fatty acids and eicosanoids, are expressed in sebaceous glands (SGs) and SZ95 sebocytes. Specifically, PPARy promotes sebocyte development and lipogenesis and is involved in oxidative stress-mediated prostaglandin E2 production, inducing COX-2 expression in these cells. Prostaglandins, synthesized in response to various stimuli, depend on cyclooxygenase enzymes (COX-1 and COX-2). COX-2, especially, is crucial in sebaceous gland development, as seen in transgenic mice with COX-2 overexpression, leading to sebaceous gland hyperplasia and increased sebum production. Additionally, growth factors like insulin-like growth factor 1 (IGF-1) play a significant role in sebocyte lipid synthesis by inducing SREBP-1 , which regulates genes of fatty acid synthesis.

[0008] High sebum production in sebocytes can lead to low linoleate levels in sebaceous esters, causing essential fatty acid deficiency and follicular hyperkeratosis, which results in comedo formation. Drug-induced suppression of sebum production increases sebum linoleate concentration, alleviating this issue. Excessive sebum production, particularly on the face, leads to an oily, greasy appearance, large pores, and is a common concern globally, affecting a significant portion of women in the US and Japan. This overproduction blocks pores, feeds skin bacteria, and can cause blemishes like comedones and more severe conditions like acne. Acne vulgaris, a common inflammatory skin condition, is linked to sebaceous gland overactivity, with sebum excretion rate correlating with its severity.

[0009] Excessive sebum production also affects hair care, causing greasy hair and being a major cosmetic concern. Various treatments, often using natural ingredients, target scalp sebum overproduction. Moreover, seborrhea, a result of excessive sebum, contributes to dandruff and seborrheic dermatitis, affecting half the global population. These conditions involve scalp flaking, itching, and inflammation, influenced by sebaceous secretions, scalp microflora, and individual susceptibility. Enlarged skin pores, a cosmetic concern for many, are caused by factors like high sebum excretion, reduced elasticity around pores, and increased hair follicle volume. Reducing sebum production and accumulation is a key strategy in managing these skin pore issues.

[0010] Furthermore, high levels of sebum can also disrupt the natural balance of the skin microbiome, which is crucial for skin health. This imbalance can weaken the skin's barrier function, making it more susceptible to infections and inflammatory reactions. Inflammatory skin conditions like akne, seborrheic dermatitis and rosacea are also associated with excessive sebum production.

[0011] Additionally, the composition of sebum itself can play a role in skin inflammation. Changes in the concentration of specific lipids within sebum can influence the skin's inflammatory response. For instance, increased levels of certain fatty acids in sebum have been linked to inflammatory processes in the skin.

[0012] Notably, while high sebum production can contribute to skin inflammation, it is often interlinked with other factors such as hormonal changes, genetics, diet, and environmental stressors. Effective management of skin inflammation due to high sebum production typically involves a combination of topical treatments, dietary changes, and, in some cases, systemic medication, aimed at regulating sebum production and addressing the underlying inflammatory processes.

[0013] Furthermore, compounds suitable to regulate sebum production can also find application in products for intimate hygiene, since the female external genitals have many sebaceous glands. Mons pubis, labia majora, labia minora and the external side of the vaginal vestibule are rich in sebaceous glands and their sebum secretion interacts with the bacterial microflora, regulating the pH of the genital area. The fresh sebum does not contain significant quantities of free fatty acids, but these are released as an effect of the lipases produced by bacteria, inducing the acidification of the genital environment. The regulation of sebum can therefore represent an important condition for preventing alterations of the genital microflora, which are associated with irritations and / or itching.

[0014] The pursuit of agents capable of reducing sebum production represents a prime example where high global demand aligns with increasing industry interest. Ideally, these agents should be naturally derived, easy to manufacture, and possess a stable shelf life.. Their versatility in safety and applicability across various products is crucial, especially in cosmetics and dermatological preparations for skin and hair care, as well as in intimate hygiene products. This approach not only meets the growing consumer demand for natural and effective solutions but also paves the way for innovative advancements in personal care.

[0015] Therefore, the primary object of the present invention was to provide a sebum-reducing blend for topical application that exhibits a more effective sebum-reduction on the skin compared to compounds known in the art. Another object is to provide a blend that meets the increasing customers’ expectation for naturally derived products. Further, one object is to provide a sebum-reducing blend that is particularly efficient in decreasing skin inflammation, at least in an additive manner, preferably in a synergistic manner.

[0016] Further objects underlying the present invention follow from the description below and the present patent claims.

[0017] Surprisingly, it was found that the blend of Tetraselmis suecica extract and Laminaria Saccharina ferment exhibit a superior (up to synergistic) effect and reduce skin sebumproduction more effective.

[0018] According to a first aspect of the present invention, the stated objects are achieved by a composition comprising a) Tetraselmis suecica extract; and b) Laminaria saccharina ferment.

[0019] In general, the production of Tetraselmis suecica extract involves a streamlined process starting with controlled cultivation in photobioreactors or open ponds to optimize growth. Once the algae reach the desired density, they are harvested using centrifugation or flocculation to separate the biomass from the growth medium. The extraction process then is continued, employing either solvent methods or mechanical techniques like ultrasonication to release valuable compounds from the algal cells. This is followed by purification and concentration steps, including filtration and chromatography, to isolate specific components. The extract undergoes rigorous quality control to ensure purity and biological activity before being formulated into final products. Finally, preservation techniques and appropriate packaging are used to maintain the extract's stability and extend its shelf life.

[0020] Laminaria saccharina, a type of brown alga, is fermented to produce a nutrient-rich extract with enhanced bioactive properties. Usually, the process begins with the cultivation and harvesting of Laminaria saccharina in marine environments, followed by cleaning and preparation to increase surface area for fermentation. Using specific microorganisms, such as bacteria and / or yeast, Laminaria saccharina undergoes a controlled fermentation process, optimizing conditions such as temperature, pH, and aeration. This step transforms the alga's natural components into more bioavailable compounds. After fermentation, the product is extracted and purified, isolating the potent ferment. Finally, the ferment is stabilized and packaged to maintain efficacy and extend shelf life. The resulting Laminaria saccharina ferment is valued in skincare products for its hydrating, anti-aging, and protective benefits.

[0021] WO 2019166520A1 discloses the use of Tetraselmis suecica extract as a topical cosmetic.

[0022] FR2980698A1 discloses a blend of a brown algae extract and a green algae extract. The document proposes using a combination of macroalgae and microalgae extracts to improve the condition of oily and acne-prone skin. Specifically, the macroalgae extract is derived from the brown algae Fucus spiralis, and the microalgae extract comes from the green microalgae Tetraselmis chui, grown in a culture enriched with trace elements, particularly zinc.

[0023] Further, in the patent family of FR2858771 a blend of the brown algae Macrocystis pyrifera and Tetraselmis suecica primarily aiming to enhance the skin's relief and micro-relief, making it especially useful for skin texture improvement.

[0024] However, none of the prior art claims or discloses the combination of Tetraselmis suecica extract and Laminaria Saccharina ferment and a resulting superior, or even synergistic effect for sebum-reduction.

[0025] In one embodiment of the invention there is provided a composition according to the first aspect, wherein Tetraselmis suecica extract is obtained by using water, ethanol, methanol, ethyl acetate, isopropanol, 2-propanone, and / or hexane as extractant.

[0026] Preferably, the Tetraselmis suecica extract is obtained by using water as extractant.

[0027] Using water for the extraction of Tetraselmis suecica extract for skincare products offers significant advantages over organic solvents like ethanol, methanol, ethyl acetate, isopropanol, 2-propanone, and hexane. The use of water - compared to organic solvents may reduce the risk of skin irritation and allergies, making it more compatible with the skin's natural composition. This compatibility is beneficial as water-based extracts are gentle, hydrating, and less likely to disrupt the skin's barrier. Additionally, water is environmentally friendly, aligning with the increasing consumer demand for natural and eco-conscious beauty products. Furthermore, water-extracted products are more likely to meet stringent cosmetic regulations, particularly those focusing on natural and organic products. They also tend to be more stable and have a longer shelf life in aqueous-based skincare formulations. This stability is crucial for maintaining the efficacy and safety of the skincare products. Additionally, there is a growing preference among consumers for products perceived as natural and minimally processed.

[0028] Preferably, the Tetraselmis suecica extract comprises: i) >10 wt.%, preferably 11 to 25 wt.%, of total minerals; and ii) > 5 wt.%, preferably 6 to 15 wt.%, of Mannitol; and iii) > 3 wt.%, preferably 4 to 15 wt.%, of total galactose; and iv) > 4 wt.%, preferably 4 to 10 wt.%, of total glucose; and v) > 3 wt.%, preferably 4 to 10 wt.%, of total amino; and vi) > 2 wt.%, preferably 3 to 5 wt.%, of total nitrogen.

[0029] According to one embodiment of the present invention there is a composition, wherein the Laminaria saccharina ferment comprises 55 to 65 wt.% water, 10 to 20 wt.% ethanol, 20 to 30 wt.% Saccharomyces / Laminaria saccharina ferment, 0,25 to 5 wt.% saccharose, preferably 57.5 to 62.5 wt.% water, 12 to 17 wt.% ethanol, 22 to 27 wt.% Saccharomyces / Laminaria saccharina ferment, 0.5 to 2 wt.% Saccharose.

[0030] Preferably, the ratio of Tetraselmis suecica extract to Laminaria saccharina ferment is between 1 :200 to 200:1 , 1 :100 to 100:1 , 1 :60 to 60:1 , 1 :40 to 40:1 , 1 :20 to 20:1 , 1 :10 to 10:1 or 1 :5 to 5:1.

[0031] Advantageously, the blend of Tetraselmis suecica extract and Laminaria saccharina according to the present invention, in particular as described herein as preferred, at least has a strong, up to a synergistic, effect on sebum-reduction (cf. Figure 1 (FIG 1)).

[0032] According to one embodiment of the present invention there is a composition, wherein the total amount of Tetraselmis suecica extract and Laminaria saccharina ferment is present at a concentration of at least 0.001 wt.%, 0.005 wt.%, 0.01 wt.%, 0.015 wt.%, 0.02 wt.% or 0.025 wt.%; and / or of at most 0.5 wt.%, 0.2 wt.%, 0.1 wt.%, 0.08 wt.%, 0.07 wt.%, 0.06 wt.% or 0.05 wt.%, based on the total weight of the composition.

[0033] According to a second aspect of the present invention there is a cosmetic or pharmaceutical composition, preferably a dermatological, skin care or hair care product, comprising the composition according to the invention, as described herein, particularly, as described herein as preferred.

[0034] According to one embodiment of the present invention there is a cosmetic or pharmaceutical composition, wherein the cosmetic or pharmaceutical composition is a topically applicable product.

[0035] Preferably, there is a cosmetic or pharmaceutical composition, further comprising water and at least one dermatologically, skin care or hair care acceptable carrier, adjuvant and / or auxiliary substance, including alcohols, polyhydric alcohols, including glycerol, high- molecular weight compounds, mono-, di- or polysaccharides, fats, fatty acids, oils, waxes, surfactants, emulsifiers, micelle water, tonics, soaps, tenside formulations, gels, preservatives and perfumes.

[0036] The cosmetic or pharmaceutical composition according to the present invention can be used in combination with carriers suitable for topical application, comprising all cosmetic or skin care products known in the art, such as cleanser, toner, moisturizer, sunscreen, serum, eye cream, face mask, exfoliant, acne treatment, face oil, makeup primer, foundation, concealer, highlighter, blush, bronzer, setting powder, eyeshadow, eyeliner, mascara, lip balm, lip scrub, lipstick, lip gloss, makeup remover, anti-aging cream, night cream, face mist, hand cream, body lotion, body oil, body scrub, self-tanner, foot cream, nail polish, cuticle oil, hair removal cream, tattoo cream, scar cream, skin brightener, skin soothing gel, skin barrier cream, skin tightening serum, hyaluronic acid serum and Aloe Vera gel, but not limited thereof.

[0037] Preferably, there is a cosmetic or pharmaceutical composition, wherein the total amount of the Tetraselmis suecica extract and the Laminaria saccharina ferment is at a concentration in the range of 0.05 to 5 wt.%, preferably, 0.1 to 3 wt.%, more preferably 1 to 2 wt.%, based on the total amount of the cosmetic or pharmaceutical composition.

[0038] A further aspect according to the present invention is a use, optionally non-therapeutic use, of a composition or of a cosmetic or pharmaceutical composition, according to the present invention, preferably any one of the above aspects and embodiments, for sebum reduction of the human or animal skin.

[0039] Another aspect in connection with the present invention is a cosmetic, non-therapeutic method comprising: topically applying a composition or a cosmetic composition, according to the present invention, preferably any one of the above aspects and embodiments, to human or animal skin.

[0040] In one embodiment of the present invention there is a composition or pharmaceutical composition according to any one of the previous aspects and embodiments, for use in treating and / or preventing skin diseases.

[0041] Preferably, there is a composition or product, according to the previous embodiment, wherein the skin diseases are skin diseases caused by, promoted by, and / or associated with sebum production or overproduction, including dysfunctions of human hair and / or skin, seborrhoeic dermatitis, acne vulgaris, wound healing, postinflammatory hyperpigmentation, inflammatory related diseases, dandruff or pityriasis versicolor.

[0042] High sebum production in the skin can lead to increased secretion of Interleukin 8 (IL-8), a chemokine responsible for inflammatory responses like recruiting neutrophils and their degranulation. Stress factors such as UV radiation and oxidative stress can trigger IL-8 secretion from various cell types, including keratinocytes. This heightened IL-8 secretion results in local inflammation, which is evident on the skin through symptoms like redness, irritation, and pain. Therefore, reducing IL-8 levels under stress conditions serves as a valuable indicator of the anti-irritant activity of cosmetic compounds. This is employed in an experimental setup to demonstrate that the blend of Tetraselmis suecica extract and Laminaria Saccharina ferment exhibits an anti-inflammatory effect, shown in Figure 2 (FIG 2).

[0043] Also described herein is a method of treating a skin disease comprising: topically applying a composition or a pharmaceutical composition, according to the present invention, preferably any one of the previous aspects or embodiments, to human or animal skin.

[0044] Also described herein is a method as described above, wherein the skin disease is a skin disease caused by, promoted by, and / or associated with sebum production or overproduction, including dysfunctions of human hair and / or skin, seborrhoeic dermatitis, acne vulgaris, wound healing, postinflammatory hyperpigmentation, inflammatory related diseases, dandruff or pityriasis versicolor. Brief Description of the Figures

[0045] FIG 1 :

[0046] Sebum-reducing effect measured as % sebogenesis for SymControl Care, which contained 2.5 % Tetraselmis suecica extract, (Tetra) and Laminaria saccharina ferment (LS), and a blend of Tetra and LS, at different concentrations.

[0047] FIG 2:

[0048] Results of an enzyme linked immunosorbance assay (ELISA) from cell supernatants utilizing antibodies detecting the IL-8. The IL-8 produced and secreted by cells will is shown as %IL-8, dependent on the concentration of the blend of algae.

[0049] Examples

[0050] Example 1 : Effect of Tetraselmis suecica extract and / or Laminaria saccharina ferment on sebogenesis.

[0051] To measure the effect of a Laminaria saccharina ferment and SymControl Care, which contained 2.5 % Tetraselmis suecica extract, on sebogenesis, human stem cell derived sebocytes (PCi sebocytes) were generated (Phenocell, France). The stem cells had been obtained from human blood donors and differentiated to sebocytes, which had been further cultivated. Lipid synthesis was induced by arachidonic acid (10pM) and analyzed by high content imaging lipid staining after 48h. Specifically, the fluorescent neutral lipid dye 4,4- difluoro-1 ,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene (BODIPY) was used to stain lipids to enable their quantification. The fluorescence signal was normalized to the cell count. The quantitative results are shown in Figure 1 (FIG 1).

[0052] Example 2: Influence of blend of algae on IL-8 secretion

[0053] For an Elisa assay, HaCaT cells were seeded at a density of 2x104cells per well in a 48- well plate and incubated at 37°C for 24 hours. Following the incubation period, the supernatant was removed, and a blend of algae was applied to each well at a volume of 10Opl. The cells were then incubated for an additional 24 hours at 37°C. Subsequently, stimulants were applied; specifically, IL-1 p at a concentration of 1 ng / ml and a medium change, each at a volume of 100 pl per well. After a further incubation period of 2 hours at 37°C, the supernatant was collected for sample recovery. Finally, the IL-8 concentration in the collected samples was quantified using an ELISA assay. The quantitative results are shown in Figure 2 (FIG 2).

Claims

Claims1 . Composition comprising a) Tetraselmis suecica extract; and b) Laminaria saccharina ferment.

2. Composition of claim 1 , wherein Tetraselmis suecica extract is obtained by using water, ethanol, methanol, ethyl acetate, isopropanol, 2-propanone, and / or hexane as extractant.

3. Composition of claim 1 or claim 2, wherein the Tetraselmis suecica extract comprises: i) >10 wt.%, preferably 11 to 25 wt.%, of total minerals; and ii) > 5 wt.%, preferably 6 to 15 wt.%, of Mannitol; and iii) > 3 wt.%, preferably 4 to 15 wt.%, of total galactose; and iv) > 4 wt.%, preferably 4 to 10 wt.%, of total glucose; and v) > 3 wt.%, preferably 4 to 10 wt.%, of total amino; and vi) > 2 wt.%, preferably 3 to 5 wt.%, of total nitrogen; wherein wt.% are based on total Tetraselmis suecica extract dry weight.

4. Composition of any of the preceding claims, wherein the Laminaria saccharina ferment comprises 55 to 65 wt.% water, 10 to 20 wt.% Ethanol, 20 to 30 wt.% Saccharomyces / Laminaria saccharina Ferment, 0,25 to 5 wt.% Saccharose, preferably 57.5 to 62.5 wt.% water, 12 to 17 wt.% Ethanol, 22 to 27 wt.% Saccharomyces / Laminaria saccharina Ferment, 0.5 to 2 wt.% Saccharose.

5. Composition of any of the preceding claims, wherein the ratio of Tetraselmis suecica extract to Laminaria saccharina ferment is between 1 :200 to 200:1 , 1 :100 to 100:1 , 1 :60 to 60:1 , 1 :40 to 40:1 , 1 :20 to 20:1 , 1 :10 to 10:1 or 1 :5 to 5:1.

6. Composition of any one of the preceding claims, wherein the total amount of Tetraselmis suecica extract and Laminaria saccharina ferment is present at a concentration of at least 0.001 wt.%, 0.005 wt.%, 0.01 wt.%, 0.015 wt.%, 0.02 wt.% or 0.025 wt.%; and / or of at most 0.5 wt.%, 0.2 wt.%, 0.1 wt.%, 0.08 wt.%, 0.07 wt.%, 0.06 wt.% or 0.05 wt.%, based on the total weight of the composition.

7. Cosmetic or pharmaceutical composition, preferably a dermatological, skin care or hair care product, comprising the composition of any one of claims 1 to 6.

8. Cosmetic or pharmaceutical composition of claim 7, wherein the cosmetic or pharmaceutical composition is a topically applicable product.

9. Cosmetic or pharmaceutical composition of claim 7 or 8, further comprising water and at least one dermatologically, skin care or hair care acceptable carrier, adjuvant and / or auxiliary substance, including alcohols, polyhydric alcohols, including glycerol, high-molecular weight compounds, mono-, di- or polysaccharides, fats, fatty acids, oils, waxes, surfactants, emulsifiers, micelle water, tonics, soaps, tenside formulations, gels, preservatives and perfumes.

10. Cosmetic or pharmaceutical composition of any one of claims 7 to 9, wherein a total amount of Tetraselmis suecica extract and Laminaria saccharina ferment is at a concentration in the range of 0.05 to 5 wt.%, preferably, 0.1 to 3 wt.%, more preferably 1 to 2 wt.%, based on the total weight of the cosmetic or pharmaceutical composition.11 . Use, optionally non-therapeutic use, of a composition as defined in any one of claims 1 to 6; or of a cosmetic or pharmaceutical composition as defined in any one of claims 7 to 10; for sebum and / or pore size reduction of the human or animal skin.

12. Cosmetic, non-therapeutic method comprising: topically applying a composition as defined in any one of claims 1 to 6; or a cosmetic composition as defined in any one of claims 7 to 10; to human or animal skin.

13. Composition of any one of claims 1 to 6; or pharmaceutical composition of any one of claims 7 to 10; for use in treating and / or preventing skin diseases.

14. Composition or product of claim 13, wherein the skin diseases are skin diseases caused by, promoted by, and / or associated with sebum production or overproduction, including dysfunctions of human hair and / or skin, seborrhoeic dermatitis, acne vulgaris, wound healing, postinflammatory hyperpigmentation, inflammatory related diseases, dandruff or pityriasis versicolor.

Images